Evolution Research Group
Classification
Private
About
About
Evolution Research Group is a privately-held clinical research site company specializing in the execution of complex inpatient and outpatient clinical trials across various therapeutic areas. ERG's centralized operations encompass quality assurance, patient recruitment, budgeting, contracting, and technology integration, ensuring consistent excellence across its network of clinical sites. The organization boasts over 400 inpatient beds and a robust database of more than 215,000 patients, supported by a centralized recruitment and marketing team, local community outreach programs, and long-standing referral relationships. In addition to its clinical trial capabilities, ERG offers consulting services to pharmaceutical companies and contract research organizations (CROs). These services include access to key opinion leaders in various therapeutic areas, rater training, centralized data services, medical writing, study feasibility assessments, and site recommendations. Evolution Research Group was founded in 2014 by Lori Wright. Evolution Research Group headquarters are located in New Providence, New Jersey. Evolution Research Group was formerly known as Thievon-Wright Consulting Group.
Financials
Revenue & Profit
Valuation
Ratios
People
Employee Figures
Key Executives
| Name | Title | Socials | Phone | |
|---|---|---|---|---|
| John Doe | Employee | -- | ||
| Jane Doe | Employee | |||
| John Doe | Employee | |||
| John Doe | Employee |
401K
Deals
M&A2024-03-15Completed
Investor Sponsors NorthBridge PE | Stake Tags 100% |
Deal Amount $120M | Is PE deal Yes |
Target Company Valuation $1.20 MM | Is deal PE backed Yes |
Techniques Acquisition of Assets, Taken Private | Total Acquired 100% |
Investor Sponsors
Deal Amount
$120M
Target Company Valuation
$1.20 MM
Techniques
Acquisition of Assets, Taken Private
Stake Tags
100%
Is PE deal
Yes
Is deal PE backed
Yes
Total Acquired
100%
Secondary Transaction2023-09-01Canceled
Investor Sponsors -- | Stake Tags Majority |
Deal Amount Undisclosed | Is PE deal No |
Target Company Valuation -- | Is deal PE backed Yes |
Techniques Secondary Sale, Management Buy-out (MBO) | Total Acquired 65% |
Investor Sponsors
--
Deal Amount
Undisclosed
Target Company Valuation
NaN
Techniques
Secondary Sale, Management Buy-out (MBO)
Stake Tags
Majority
Is PE deal
No
Is deal PE backed
Yes
Total Acquired
65%
Funding
Keywords
Keywords
Classified
Private
© 2026 PrivCo Holding Inc. All rights reserved.
No AI Training or Automated Data Extraction.
Use of this page or any content or data made available by PrivCo for scraping, crawling, indexing, caching, extracting, copying, reproducing, storing, or for training or developing any artificial intelligence or machine learning system is strictly prohibited without prior written consent. All access to and use of this page and PrivCo's services are subject to the PrivCo Terms of Use: https://www.privco.com/terms-of-use. No license or right is granted by implication or otherwise.